Literature DB >> 15279417

[Structural and immunohistochemical changes of conjunctiva induced by topical glaucoma medication].

A Nenciu1, C Stefan, Carmen Ardelean.   

Abstract

PURPOSE: The topical medication represents the first line therapy for the primary open angle glaucoma. The study is aimed at assessing the structural and immunohistochemical changes of conjunctiva induced by topical glaucoma medication.
METHODS: For this purpose, we carried out a 40 weeks, prospective, experimental, epidemiological-operational and randomized study enrolling 18 patients (36 eyes) with recently primary open angle glaucoma. The eyes were divided into treatment (non-selective beta blockers or selective, prostaglandin analogues, topical carbonic anhydrase inhibitors) in four groups. The assessment was performed by comparison with control group (4 patients) who was instilled with natural tears (with different preservative). Both the cytology and the conjunctival biopsy specimens were investigated by histological exams and immunohistochemistry using different monoclonal antibodies. The study was performed by collaboration with The National Institute of Research and Development in Pathology and Biomedical Sciences-"V. Babes"-Bucharest.
RESULTS: The morphometric analysis of histological sections of conjunctiva showed the following changes: squamous metaplasia (significant increases in the thickness and number of epithelial cell layers), inflammation (increase the number of lymphocytes, macrophages and fibroblasts) and subconjunctival fibrosis. According to the type of medication, we observed the significant increase of subepithelial collagen density and degenerative changes of fibrocytes, the reduction of extracellular matrix and also the up-regulation of antibodies against matrix metalloproteinase and allergic changes. According to structural changes, the immunohistochemistry confirmed the tendency of chronic inflammation.
CONCLUSIONS: This study revealed important structural and immunohistochemical changes of conjunctiva after topical glaucoma medication. The category and the intensity of these changes are dependent on the sort of therapy and the topical treatment period. The findings showed that benzalkonium chloride (the most common preservative of antiglaucoma drugs) is a major factor for conjunctival metaplasia.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15279417

Source DB:  PubMed          Journal:  Oftalmologia        ISSN: 1220-0875


  6 in total

Review 1.  Effects of common topical antiglaucoma medications on the ocular surface, eyelids and periorbital tissue.

Authors:  J Javier Servat; C Robert Bernardino
Journal:  Drugs Aging       Date:  2011-04-01       Impact factor: 3.923

2.  Phospholipases A2 in normal human conjunctiva and from patients with primary open-angle glaucoma and exfoliation glaucoma.

Authors:  Minna Helin; Seppo Rönkkö; Tuomo Puustjärvi; Markku Teräsvirta; Hannu Uusitalo
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-01-15       Impact factor: 3.117

3.  Conjunctival structure of glaucomatous eyes treated with anti-glaucoma eye drops: a cross-sectional study using anterior segment optical coherence tomography.

Authors:  Makoto Gozawa; Yoshihiro Takamura; Kentaro Iwasaki; Shogo Arimura; Masaru Inatani
Journal:  BMC Ophthalmol       Date:  2020-06-19       Impact factor: 2.209

4.  Ocular Surface Disease with BAK preserved Travoprost and Polyquaternium 1(Polyquad) preserved Travoprost.

Authors:  Suresh Kumar; Tanu Singh; Parul Ichhpujani; Sanchi Vohra
Journal:  Rom J Ophthalmol       Date:  2019 Jul-Sep

5.  Differences in the histopathology and matrix metalloproteinase expression in Tenon's tissue of primary open-angle glaucoma and primary angle-closure glaucoma.

Authors:  Je Hyun Seo; Ki Ho Park; Yu Jeong Kim; Young Cheol Yoo; Shin Hee Kang; Dong Myung Kim
Journal:  Korean J Ophthalmol       Date:  2008-03

6.  Ocular surface alterations and topical antiglaucomatous therapy: a review.

Authors:  Alessandro G Actis; Teresa Rolle
Journal:  Open Ophthalmol J       Date:  2014-10-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.